Routine new-hire equity grant — no trading signal. Monitor upcoming quarterly results for commercial progress on Amtagvi and pipeline updates.
Price Chart
Executive Summary
Iovance Biotherapeutics granted inducement stock options covering 93,340 shares to 13 new non-executive employees under its 2021 Inducement Plan. The options have an exercise price of $3.70 and vest over three years. This is a routine equity grant for new hires, not a material financial event.
Key Facts
- 93,340 shares of common stock granted as inducement stock options to 13 new non-executive employees.
- Exercise price of $3.70, equal to the closing price on the grant date (May 21, 2026).
- Options vest over three years: one-third on first anniversary, remainder in quarterly installments.
- Granted under the Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
Financial Impact
93,340 shares at $3.70 per share = approximately $345,000 in potential option value; immaterial relative to Iovance's $1.7B market cap.
Risk Factors
- No material risk from this grant; dilution is negligible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300384 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $8.06 $10.64 | ▲ +32.01% | ▲ +30.70% | $14.19 (+75.99%) |
Aug 6, 2026 8w ago | 8-K | $6.34 $8.79 | ▲ +38.64% | ▲ +39.04% | $14.19 (+123.74%) |
Aug 6, 2026 8w ago | 8-K | $6.21 $8.70 | ▲ +40.10% | ▲ +39.50% | $14.19 (+128.42%) |
Jul 16, 2026 11w ago | Court Ruling | $4.66 $6.52 | ▼ −39.91% | ▼ −36.30% | $14.19 (−204.40%) |
Jul 2, 2026 13w ago | 8-K | $4.31 $4.69 | ▲ +8.82% | ▲ +9.23% | $14.19 (+229.12%) |
Jun 19, 2026 14w ago | Press Release | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.19 (+249.38%) |
Jun 18, 2026 15w ago | S-3ASR | $4.06 $5.00 | ▲ +23.15% | ▲ +23.30% | $14.19 (+249.38%) |
Jun 10, 2026 16w ago | 8-K | $3.96 $4.37 | ▲ +10.35% | ▲ +8.46% | $14.19 (+258.21%) |
May 22, 2026 18w ago | Press Release | $4.10 $4.34 | ▲ +5.87% | ▲ +7.81% | $14.19 (+245.98%) |
Apr 28, 2026 22w ago | DEFA14A | $3.31 $4.30 | ▲ +29.91% | ▲ +23.86% | $14.19 (+328.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access